T 82

Drug Profile

T 82

Latest Information Update: 24 Apr 2002

Price : $50

At a glance

  • Originator SSP Co
  • Developer Arena Pharmaceuticals; SSP Co
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Acetylcholinesterase inhibitors; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Apr 2002 Discontinued - Preclinical for Alzheimer's disease in Japan (unspecified route)
  • 24 Apr 2002 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
  • 25 May 2001 Phase-II clinical trials for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top